Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) is expected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect Kyverna Therapeutics to post earnings of ($0.68) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.05. On average, analysts expect Kyverna Therapeutics to post ($2.70) EPS for the current fiscal year and ($2.95) EPS for the next fiscal year.
Kyverna Therapeutics Stock Performance
Shares of NASDAQ KYTX traded up $0.06 during trading on Wednesday, hitting $5.22. The company had a trading volume of 78,740 shares, compared to its average volume of 908,823. The stock has a 50 day simple moving average of $6.78 and a 200 day simple moving average of $8.05. Kyverna Therapeutics has a 12 month low of $5.09 and a 12 month high of $13.67. The firm has a market capitalization of $322.87 million, a P/E ratio of -1.81 and a beta of 2.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 9.06 and a current ratio of 9.06.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on KYTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, September 21st. HC Wainwright reissued a “buy” rating on shares of Kyverna Therapeutics in a research note on Thursday, October 22nd. William Blair raised Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Benchmark reiterated a “buy” rating on shares of Kyverna Therapeutics in a report on Friday, September 25th. Finally, Needham & Company LLC set a $25.00 price objective on Kyverna Therapeutics in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.00.
About Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biotechnology company developing engineered T-cell therapies for patients with severe autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing B cells, which play a central role in many autoimmune disorders, with the goal of achieving deep and durable disease remission.
Kyverna’s lead investigational product, KYV-101, is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The treatment is being evaluated in clinical studies for conditions including lupus nephritis, systemic sclerosis, multiple sclerosis and other serious autoimmune diseases.
Featured Stories
- Five stocks we like better than Kyverna Therapeutics
- High Voltage Returns: Talen Energy Powers the Data Center Rush
- 3 Dividend Increases Above 10%, But Which Offers the Most Income?
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
